Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jan 8:9:1460.
doi: 10.3389/fonc.2019.01460. eCollection 2019.

A Meta-Analysis of the Efficacy and Toxicity of Twice-Daily vs. Once-Daily Concurrent Chemoradiotherapy for Limited-Stage Small Cell Lung Cancer Based on Randomized Controlled Trials

Qian Wu  1   2 , Yiting Xiong  1   2 , Shujuan Zhang  2   3 , Xinling Chen  2   3 , Fengming Yi  3 , Yiping Wei  1 , Wenxiong Zhang  1
Affiliations

A Meta-Analysis of the Efficacy and Toxicity of Twice-Daily vs. Once-Daily Concurrent Chemoradiotherapy for Limited-Stage Small Cell Lung Cancer Based on Randomized Controlled Trials

Qian Wu et al. Front Oncol. .

Abstract

Background: Currently, the accepted standard management of limited-stage small cell lung cancer (SCLC) is concurrent chemoradiotherapy (CCRT), but the frequency of radiotherapy is controversial. Therefore, this meta-analysis, which compared the efficacy and toxicity between twice-daily (BID) and once-daily (OD) CCRT, was performed to help clinicians make better decisions. Methods: Relevant randomized controlled trials (RCTs) were collected by searching the PubMed, Ovid MEDLINE, Embase, ScienceDirect, Web of Science, the Cochrane Library, Scopus and Google Scholar databases to assess antitumor effects (overall survival, OS; progression-free survival, PFS; overall response rate, ORR) and toxicity (adverse effects, AEs). Results: We screened 1499 articles and included 5 RCTs including 1421 patients. We found that BID CCRT improved OS (hazard ratio, HR = 0.88, 95% confidence interval, CI 0.78-0.99, p = 0.03), the 1-year OS rate (OSR-1y, risk ratio, RR = 1.07, 95%CI 1.01-1.13, p = 0.03), and OSR-4y (RR = 1.22, 95%CI 1.03-1.43, p = 0.02), with better trends in OSR-2y, OSR-3y, and OSR-5y, compared to OD CCRT. In addition, BID CCRT had a higher complete response (CR, RR = 1.31, 95%CI 1.01-1.70, p = 0.04) than OD CCRT. PFS (HR = 0.92, 95%CI 0.79-1.07, p = 0.29), annual PFS rate, ORR (RR = 0.99, 95%CI 0.93-1.05, p = 0.72), and AEs for all grades (RR = 1.00, 95%CI 0.98-1.01, p = 0.57), and grades 3-5 (RR = 1.02, 95%CI 0.95-1.09, p = 0.60) were similar between the two arms. Conclusions: BID CCRT appears to be better than OD CCRT for limited-stage SCLC, with better antitumor effects (OS, OSR, and CR) and similar AEs. However, the high levels of AEs in both arms should be taken as a sign of caution. More large sample and high-quality RCTs need to be conducted to confirm our conclusions.

Keywords: concurrent chemoradiotherapy; limited-stage small cell lung cancer; meta-analysis; once-daily; twice-daily.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow chart of literature selection.
Figure 2
Figure 2
Forest plots of OS (A) and PFS (B).
Figure 3
Figure 3
Annual OSR (A) and annual PFSR (B).
Figure 4
Figure 4
Forest plots of ORR (A), CR (B), and PR (C).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA. (2019) 69:7–34. 10.3322/caac.21551 - DOI - PubMed
    1. Pezzi TA, Schwartz DL, Mohamed AS, Welsh JW, Komaki RU, Hahn SM, et al. . Barriers to combined-modality therapy for limited-stage small cell lung cancer. JAMA Oncol. (2018) 4:e174504. 10.1001/jamaoncol.2017.4504 - DOI - PMC - PubMed
    1. Howlader N, Noone A, Krapcho M, Miller D, Brest A, Yu M, et al. SEER Cancer Statistics Review, 1975–2016. Bethesda, MD: National Cancer Institute; Available online at: https://seer.cancer.gov/csr/1975_2016/, based on November 2018 SEER data submission, posted to the SEER web site, April 2019.
    1. Gazdar AF, Bunn PA, Minna JD. Small-cell lung cancer: what we know, what we need to know and the path forward. Nat Rev Cancer. (2017) 17:725–37. 10.1038/nrc.2017.87 - DOI - PubMed
    1. van Loon J, Dingemans A-MC. Is concurrent chemoradiotherapy also the best treatment for elderly patients with limited-stage small cell lung cancer?–What the CONVERT data can tell us. J Thor Oncol. (2019) 14:13–15. 10.1016/j.jtho.2018.11.005 - DOI - PubMed

Publication types

LinkOut - more resources